SNY
April 24, 2025 - AI Summary
Overvalued by 6.6% based on the discounted cash flow analysis.
Market cap | $125.48 Billion |
---|---|
Enterprise Value | $139.32 Billion |
Dividend Yield | $2.21215 (4.43388756927949%) |
Earnings per Share | $2.3 |
Beta | 0.41 |
Outstanding Shares | 2,467,800,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 17.32 |
---|---|
PEG | 26.55 |
Price to Sales | 2.42 |
Price to Book Ratio | 1.69 |
Enterprise Value to Revenue | 2.6 |
Enterprise Value to EBIT | 12.56 |
Enterprise Value to Net Income | 18 |
Total Debt to Enterprise | 0.16 |
Debt to Equity | 0.29 |
No data
No data
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the c...